Reuters logo
BRIEF-Helsinn Group and Mei Pharma announce first patient dosed in phase 2 dose-optimization study of pracinostat and azacitidine
June 14, 2017 / 12:48 PM / 6 months ago

BRIEF-Helsinn Group and Mei Pharma announce first patient dosed in phase 2 dose-optimization study of pracinostat and azacitidine

June 14 (Reuters) - Mei Pharma Inc

* Helsinn group and Mei Pharma announce first patient dosed in phase 2 dose-optimization study of pracinostat and azacitidine in myelodysplastic syndrome

* Mei Pharma says data from first stage is expected in Q1 of 2018 Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below